报价延迟最少15分钟:2026/04/21 20:26 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
68.41 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
2.56/13.57
|
|
企业价值
10.38B
|
| 资产负债 |
|
每股账面净值
0.41
|
| 现金流量 |
|
现金流量率
0.08
|
| 损益表 |
|
收益
1.40B
|
|
每股收益
6.59
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally. |
